Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis
- Conditions
- Ischemic Stroke
- Interventions
- Procedure: DES groupProcedure: BMS group
- Registration Number
- NCT02197559
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Brief Summary
The study hypothesizes that Drug -eluting stents are more effective in preventing restenosis than Bare-metal stents after Vertebral Artery Ostium stenting
- Detailed Description
The vertebral artery ostium stenosis was one of the higher risk of the ischemia stroke in China. In the mean time ,more and more people accept revascularization. There are no prospective studies for comparison of prevention of restenosis after Drug -eluting stents and Bare-metal stents until now.
The main aim of this study is to observe the following details:
1. Late loss in lumen diameter in follow-up ≥50%
2. Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs
3. Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs
Secondary endpoint:
brain, gastrointestinal and urinary system bleeding in 12 months follow-up
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 168
- symptomatic posterior circulation ischemia including monor stroke (mRS ≤2) or TIA result from the stenosis in the vertebral artery ostium.
70% to 99% stenosis of vertebral artery ostium.
- etiology of stenotic lesions not atherosclerosis patients had undergone previos interventions on the vertebral artery ostium ipsilateral severe stenotic lesions in subclavian artery involved as well as vertebral artery ostium
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description BMS group, DES group DES group All the participants in this group will be performed with bare-metal stents or drug -eluting stents BMS group, DES group BMS group All the participants in this group will be performed with bare-metal stents or drug -eluting stents
- Primary Outcome Measures
Name Time Method Late loss in lumen diameter in follow-up ≥50% 1 year Late loss in lumen diameter in follow-up ≥50%
Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs 12 months Death, non -fatal stroke 12 months after stent implantation associated with antiplatelet drugs
Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs 30 days Death, non -fatal stroke 30 days after stent implantation associated with antiplatelet drugs
- Secondary Outcome Measures
Name Time Method brain, gastrointestinal and urinary system bleeding in 12 months follow-up 12 months brain, gastrointestinal and urinary system bleeding in 12 months follow-up
Trial Locations
- Locations (1)
Department of neurosurgery, Xuanwu hospital
🇨🇳Beijing, China